Clinical, microbial efficacy and tolerability of Elores, a novel antibiotic adjuvant entity in ESBL producing pathogens: Prospective randomized controlled clinical trial

Results of this study indicates that Elores is more safe and effective regimen in treating ESBL producing gram-negative and gram-positive pathogens in comparison to plain ceftriaxone.